SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with a favourable outcome.

Details

Ressource 1Download: 32478936_BIB_A149616B606F.pdf (368.04 [Ko])
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_A149616B606F
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
Title
SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with a favourable outcome.
Journal
European journal of neurology
Author(s)
Lascano A.M., Epiney J.B., Coen M., Serratrice J., Bernard-Valnet R., Lalive P.H., Kuntzer T., Hübers A.
ISSN
1468-1331 (Electronic)
ISSN-L
1351-5101
Publication state
Published
Issued date
09/2020
Peer-reviewed
Oui
Volume
27
Number
9
Pages
1751-1753
Language
english
Notes
Publication types: Case Reports
Publication Status: ppublish
Abstract
The spectrum of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2), includes different neurologic manifestations of the central and peripheral nervous system.
From March through April 2020, in two university hospitals located in western Switzerland, we examined three patients with Guillain-Barré syndrome (GBS) following SARS-CoV-2.
These cases were characterized by a primary demyelinating electrophysiological pattern (Acute inflammatory demyelinating polyneuropathy or AIDP) and a less severe disease course compared to recently published case series. Clinical improvement was observed in all patients at week five. One patient was discharged from hospital after full recovery with persistence of minor neurological signs (areflexia). Two of the three patients remained hospitalized: one was able to walk and the other could stand up with assistance.
We report three cases of typical GBS (AIDP) occurring after SARS-CoV-2 infection and presenting with a favourable clinical course. Given the interval between COVID-19-related symptoms and neurological manifestations (mean of 15 days) we postulate a secondary immune-mediated mechanism rather than direct viral damage.
Keywords
COVID-19/complications, Disease Progression, Female, Guillain-Barre Syndrome/drug therapy, Guillain-Barre Syndrome/etiology, Guillain-Barre Syndrome/physiopathology, Humans, Immunoglobulins, Intravenous/therapeutic use, Middle Aged, Neural Conduction/physiology, Switzerland, Treatment Outcome, COVID-19, electrodiagnostic testing, immune-mediated disorder, immunoglobulin therapy, infection, polyradiculoneuropathy
Pubmed
Web of science
Open Access
Yes
Create date
10/06/2020 21:30
Last modification date
30/04/2021 7:13
Usage data